Galmed Pharmaceuticals
GLMD
26 hedge funds and large institutions have $11.8M invested in Galmed Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 25 → 26 (+1)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
0.01% less ownership
Funds ownership: 0.11% → 0.09% (-0.01%)
19% less capital invested
Capital invested by funds: $14.6M → $11.8M (-$2.83M)
84% less call options, than puts
Call options by funds: $80K | Put options by funds: $504K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Tidal Investments
Milwaukee,
Wisconsin
|
+$71.8K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$63.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$60.8K |
| 4 |
Millennium Management
New York
|
+$37.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.66M |
| 2 |
II
Ibex Investors
Denver,
Colorado
|
-$80.8K |
| 3 |
Morgan Stanley
New York
|
-$57.2K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
-$51K |
| 5 |
Two Sigma Advisers
New York
|
-$46K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JF
26
Jump Financial
Chicago,
Illinois
| – | -$51K | -93 | Closed |
|
|
27
Two Sigma Advisers
New York
| – | -$46K | -84 | Closed |
|
|
SFI
28
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$31K | -57 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | +$524 | +1 | New |
|
GLMD Hedge Fund Activity: Q3 2021 in Review
26 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2021, worth a combined $11.8M — down 19% from $14.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GLMD positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Tidal Investments, opening a new position worth an estimated $71.8K. The largest seller was Nantahala Capital Management, cutting an estimated $1.66M.
- 26 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2021, up from 25 in Q2 2021.
- Funds reported $11.8M of Galmed Pharmaceuticals stock for Q3 2021, down 19% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q3 2021 and 3 closed out, a net change of +1 holder.
- The largest Galmed Pharmaceuticals buyer in Q3 2021 was Tidal Investments, an estimated $71.8K added.
- The largest Galmed Pharmaceuticals seller in Q3 2021 was Nantahala Capital Management, an estimated $1.66M sold.
Based on aggregated 13F filings for Q3 2021.